Consistently, we observed that the pharmacological dual blockade of HER2 and FASN targets CSCs more efficiently than monotherapies and reduced the in vivo growth of trastuzumab-resistant HER2+ GC cells. The gene discussed is ERBB2; the disease is gastric cancer.